Plasminogen-activator inhibitor type 1 and coronary artery disease

New England Journal of Medicine

Volumn 342, Issue 24, 2000, Pages 1792-1801

  Kohler, Hans P ^a   Grant, Peter J ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FIBRIN FORMATION; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN RESISTANCE; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

CORONARY DISEASE; FIBRIN; FIBRINOLYSIS; HUMANS; INSULIN RESISTANCE; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034660437     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200006153422406     Document Type: Review

References (103)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50, 310-8.
2. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989;64:555-9.
3. Shea S, Ottman R, Gabrieli C, Stein Z, Nichols A. Family history as an independent risk factor for coronary artery disease. J Am Coll Cardiol 1984;4:793-801.
4. Michaels L. Aetiology of coronary artery disease: an historical approach. Br Heart J 1966;28:258-64.
5. Heinrich J, Balleiscn L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-9. [Erratum, Arterioscler Thromb 1994;14:1392.]
6. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9.
7. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
8. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
9. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994;90:2236-40.
10. Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987;70:1645-53.
11. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991;68:28B-35B.
12. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989;997:96-110. [Erratum, Biochim Biophys Acta 1989;999:225.]
13. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996;76:535-40.
14. Ichinose A. The physiology and biochemistry of factor XIII. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and thrombosis. 3rd ed. Vol. 1. Edinburgh, Scotland: Churchill Livingstone, 1994:531-46.
15. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999;99:299-304.
16. Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990;75:1455-9.
17. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69:381-7.
18. 2-plasmin inhibitor to fibrin. FEBS Lett 1983; 153:369-71.
19. Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986;55:325-9.
20. Kruithof EKO. Plasminogen activator inhibitors - a review. Enzyme 1988;40:113-21.
21. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990;265:109-13.
22. Owensby DA, Morton PA, Wun TC, Schwartz AL. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells: evidence that the binding protein is vitronectin. J Biol Chem 1991;266: 4334-40.
23. Kooistra T, Sprengers ED, van Hinsbergh VWH. Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. Biochem J 1986;239:497-503.
24. Declerck PJ, De Mol M, Alessi MC, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma: identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988;263:15454-61.
25. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986;77:165-9.
26. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999;99: 3050-5.
27. Hoylaerts M, Rijken DC, Lijnen HR, Collén D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982;257:2912-9.
28. Higgins DL, Vehar GA. Interaction of one-chain and two chain tissue plasminogen activator with intact and plasmin-degraded fibrin. Biochemistry 1987;26:7786-91.
29. Panel R, Black J, Gurewich V. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988;81:853-9.
30. Husain SS, Hasan AAK, Budzynski AZ. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-crosslinked and cross-linked fibrin clots. Blood 1989;74:999-1006.
31. Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA): binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J Clin Invest 1989;84:647-55.
32. Levi M, Biemond BJ, van Zonneveld A-J, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992;85:305-12.
33. Keijer J, Linders M, van Zonneveld AJ, Ehrlich HJ, de Boer JP, Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance. Blood 1991;78:401-9.
34. Siddiqi F, Odrljin TM, Fay PJ, Cox C, Francis CW. Binding of tissue-plasminogen activator to fibrin: effect of ultrasound. Blood 1998;91:2019-25.
35. Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann N Y Acad Sci 1992;667:52-63.
36. Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985;105:265-70.
37. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
38. Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994;14:1741-5.
39. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98:2241-7.
40. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
41. Francis RB Jr, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988;115:776-80.
42. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
43. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63.
44. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metroprolol: results from the Angina Prognosis Study in Stockholm. Circulation 1997;95:2380-6.
45. Bavenholm P, de Faire U, Landou C, et al. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J 1998;19:402-10.
46. Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998,136:109-14.
47. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213-21.
48. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992;89:6998-7002.
49. Preissner KT, May AE, Wohn KD, Germer M, Kanse SM. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling. Thromb Haemost 1997;78:88-95.
50. Clark RAF, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. Am J Pathol 1996;148:1407-21.
51. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383:441-3.
52. Carmeliet P, Moors L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997;96:3180-91.
53. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79: 101-6.
54. Andreotti F, Davies GJ, Hackett DR, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 65:635-7.
55. Kannel WB. Lipids, diabetes, and coronary artery disease: insights from the Framingham Study. Am Heart J 1985;110:1100-7.
56. Yano K, Reed SM, McGee DL. Ten-year incidence of coronary heart disease in the Honolulu Heart Program: relationship to biologic and life-style characteristics. Am J Epidemiol 1984;119:653-66.
57. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83:356-62.
58. Reaven GM. Role of insulin resistance in human disease. Diabetes 1983;37:1595-607.
59. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen ac tivator inhibitor I levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-62.
60. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991;91:191-205.
61. Green D, Ruth KJ, Folsom AR, Liu K. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb 1994;14:686-93.
62. Fuller JH, Keen H, Jarrett RJ, et al. Haemostatic variables associated with diabetes and its complications. BMJ 1979;2:964-6.
63. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672-6.
64. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70:380-5.
65. Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996;94: 2171-6.
66. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemost 1989;61:370-3.
67. Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight post-menopausal women. Arterioscler Thromb Vasc Biol 1996;16:381-5.
68. Bavenholm P, Proudler A, Tornvall P, et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 1995; 92:1422-9.
69. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8-17.
70. Maiello M, Boeri D, Podesta F, et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992;41: 1009-15.
71. Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati MB, Consoli A. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabctologia 1996;39: 1425-31.
72. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-I promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998;273:8225-31.
73. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993;10:27-32.
74. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992;41:890-5.
75. Panahloo A, Mohamed-Ali V, Andrés C, Denver AE, Yudkin JS. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 1998;47:637-43.
76. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8.
77. Alderman MH, Madhaven S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.
78. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
79. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999;34: 285-90.
80. Nilsson L, Gafvels M, Musakka L, et al. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. J Lipid Res 1999;40:913-9.
81. Nilsson L, Banfi C, Diczfalusy U, Tremoli E, Hamsten A, Eriksson P. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1679-85.
82. Gallicchio M, Argyriou S, Ianches G, et al. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells. Arterioscler Thromb 1994;14:815-23.
83. Orbe J, Montes R, Zabalegui N, Pérez-Ruiz A, Paramo JA. Evidence that hepirin but not hirudin reduces PAI-1 expression in cultured human endothelial cells. Thromb Res 1999;94:137-45.
84. Strandberg L, Lawrence D, Ny T. The organization of the human-plasminogen-activator-inhibitor-1 gene: implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988;176:609-16.
85. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991;11:183-90.
86. Klinger KW, Winqvist R, Riccio A, et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci U S A 1987;84: 8548-52.
87. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45.
88. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5.
89. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995;74:842-7.
90. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998;18:20-6.
91. Sironi L, Mussoni L, Prati L, et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996;16:89-96.
92. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995;74:1032-4.
93. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography Arterioscler Thromb Vasc Biol 1997;17:33-7.
94. Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18:152-6.
95. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995;74:837-41.
96. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
97. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphisms is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999;82:1121-6.
98. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997;77:730-4.
99. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998;80:1029-30.
100. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998;79:8-13.
101. Wartiovaara U, Perola M, Mikkola H, et al. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999;142:295-300.
102. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999;93:906-8.
103. Kohler HP, Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. Thromb Haemost 1999;82:1202-3.